Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMDX 2011P

Next Previous
Drug Profile

AMDX 2011P

Alternative Names: Alpha synucleinopathies targeted small molecule retinal tracer; AMDX-2011-P; AMDXP-2011-P; TAR DNA binding protein 43 targeted small molecule retinal tracer

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amydis
  • Developer Amydis; University of California, San Diego
  • Class Contrast media; Diagnostic agents; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease; Cerebral amyloid angiopathy; Open-angle glaucoma
  • Phase I Amyotrophic lateral sclerosis; Parkinson's disease
  • Research Neurodegenerative disorders

Most Recent Events

  • 23 Sep 2025 AMDX 2011P is still in phase I PROBE clinical development in Amyotrophic lateral sclerosis (Diagnosis) in USA (IV) (NCT05542576)
  • 23 Sep 2025 AMDX 2011P is still in phase I PROBE clinical development in Parkinson's disease (Diagnosis) in USA (IV) (NCT05542576)
  • 15 Mar 2025 Amydis completes phase I PROBE clinical trial in Parkinson's disease (Diagnosis) in USA (IV) (NCT05542576)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top